Group 1 - JPMorgan's long position in Wuxi AppTec's H-shares increased from 4.89% to 5.03% on November 21, 2025 [1]

证券代码：603259 证券简称：药明康德 公告编号：临 2025-072 关于股东权益变动触及 1%刻度的提示性公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 公司董事会及全体董事保证公告内容与相关股东提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少√ | | --- | --- | --- | --- | | 权益变动前合计比例 | 18.46% | | | | 权益变动后合计比例 | 17.95% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否√ | | | 是否触发强制要约收购义务 | 是□ | 否√ | | 一、 信息披露义务人及其一致行动人的基本信息 1、身份类别 投资者及其一致行动人的身份 √控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 2、信息披露义务人信息 | 信息披露义务人名称 | | | | | 投资者身份 | | 统一社会信用代码 | ...

Market Overview - The Hong Kong stock market showed a significant recovery on November 24, with all three major indices ending a streak of declines[9] - Large tech stocks performed strongly, with Kuaishou rising over 7%, and NetEase and Bilibili increasing over 5%[9] - The Hang Seng Tech Index closed at 5,546, up 2.78% for the day and 24.11% year-to-date[3] Sector Performance - Innovative pharmaceuticals and outsourcing concepts saw notable gains, with companies like Innovent Biologics rising over 6%[9] - Military stocks also performed well, with China Shipbuilding Defense up over 13%[9] - Oil stocks were weak, with China National Offshore Oil Corporation and China Oilfield Services both declining over 1%[9] U.S. Market Insights - On the same day, U.S. markets saw all three major indices close higher, driven by increased bets on a Federal Reserve rate cut[9] - The "Magnificent Seven" tech stocks, including Google and Nvidia, all rose, with Google gaining over 6%[9] - The S&P 500 index is projected to achieve double-digit annual growth according to HSBC strategists[14] Economic Indicators - The Federal Reserve is expected to cut rates in December, with market predictions showing a 70% probability[14] - The U.S. economy's third-quarter GDP report has been delayed due to a government shutdown, affecting economic analysis[14] Investment Trends - The Nasdaq Golden Dragon China Index rose by 2.82%, indicating a positive trend for Chinese concept stocks[13] - Significant inflows into semiconductor stocks were noted, with companies like Broadcom surging 11%[13]

Core Insights - The article highlights the top and bottom AH share premium rates, with Northeast Electric (00042) leading at 831.03% and Ningde Times (03750) at -4.55% [1][2][3] Premium Rate Rankings - The top three AH share premium rates are: - Northeast Electric (00042): 831.03% - Hongye Futures (03678): 270.00% - Sinopec Oilfield Service (01033): 268.92% [1][2] - The bottom three AH share premium rates are: - Ningde Times (03750): -4.55% - China Merchants Bank (03968): -1.71% - Heng Rui Medicine (01276): 3.65% [1][3] Deviation Value Rankings - The top three stocks with the highest deviation values are: - China Shipbuilding Defense (00317): 53.01% - Guanghetong (00638): 25.36% - GAC Group (02238): 22.12% [1][4] - The bottom three stocks with the lowest deviation values are: - Longpan Technology (02465): -31.76% - Northeast Electric (00042): -23.74% - Ganfeng Lithium (01772): -14.15% [1][5]

Core Viewpoint - WuXi AppTec's financial performance in the first three quarters of 2025 shows significant growth in net profit, largely driven by non-recurring gains, raising concerns about the sustainability of its profit structure [2][4][5]. Financial Performance - The company reported a revenue of 32.857 billion yuan, an 18.61% year-on-year increase, and a net profit of 12.076 billion yuan, which surged by 84.84% [2]. - Non-recurring gains contributed 2.553 billion yuan, primarily from the sale of shares in WuXi XDC Cayman Inc., with a total gain of 3.223 billion yuan [4]. - After excluding non-recurring gains, the net profit attributable to shareholders was 9.522 billion yuan, reflecting a lower growth rate of 42.51% compared to the overall net profit growth [4][5]. Revenue Structure - Revenue from domestic clients grew only 0.5% to 5.04 billion yuan, indicating stagnation, while revenue from U.S. clients increased by 31.9% to 22.15 billion yuan, and European revenue rose by 13.5% to 3.84 billion yuan [7]. - The company is heavily reliant on overseas clients, which poses risks due to geopolitical and trade policy uncertainties [7]. Business Segments - The chemical and TIDES segments showed strong growth, with increases of 29.28% and 121.1%, respectively, while testing services experienced a slight decline of 0.04% [8]. - Other business segments saw a decline of 10.47%, indicating weaknesses in certain areas [8]. Research and Development - R&D expenditures decreased to 826 million yuan, down 13.46% year-on-year, suggesting a reduction in investment in core business development [8]. Financial Pressure - Financial costs rose significantly, with expenses reaching 191 million yuan compared to a net gain of 62 million yuan in the previous year, and interest expenses increased to 227 million yuan [9]. - Short-term borrowings surged to 5.282 billion yuan, a 324.9% increase from the end of 2024 [9]. Order Backlog - The company reported a backlog of 59.88 billion yuan in ongoing business, a 41.2% increase year-on-year, but the order structure requires optimization [10]. - The addition of 621 new projects in the small molecule D&M pipeline indicates growth, but the conversion efficiency for later-stage projects remains low [10]. Future Outlook - The company faces challenges in reducing reliance on non-recurring gains and expanding its domestic market presence to mitigate geopolitical and financial pressures [11].

Core Viewpoint - Morgan Stanley's research report indicates that WuXi AppTec's valuation levels are becoming more attractive amid a stable fundamental backdrop, with a particular focus on WuXi AppTec as a preferred stock due to its robust performance and growth potential [1] Group 1: Company Performance - WuXi AppTec has raised its earnings guidance and is undergoing significant capacity expansion, particularly in the next-generation GLP-1 sector [1] - The earnings forecasts for WuXi AppTec for the years 2025 to 2027 have been increased by 3% to 4% [1] - WuXi Biologics' earnings estimates for 2025 to 2027 have been raised by 6% to 13% [1] - WuXi AppTec's subsidiary, WuXi STA, has seen its earnings projections adjusted upward by 7% to 8% [1] Group 2: Growth Projections - The compound annual growth rates (CAGR) for the three companies from 2024 to 2027 are projected to be 24%, 23%, and 37% respectively [1]

Group 1 - Morgan Stanley's research report indicates that WuXi AppTec's valuation levels are attractive amid a stable fundamental backdrop, with a particular focus on WuXi Biologics [1] - The report highlights that WuXi Biologics has raised its earnings guidance and is undergoing significant capacity expansion, with high participation in the next-generation GLP-1 sector [1] - The firm has upgraded earnings forecasts for WuXi Biologics for 2025 to 2027 by 6% to 13%, and for WuXi AppTec by 3% to 4%, designating WuXi AppTec as a top pick [1] Group 2 - The compound annual growth rates for the three companies from 2024 to 2027 are projected at 24%, 23%, and 37% respectively [1] - Other major banks, including Oriental Securities and Goldman Sachs, have also maintained positive ratings on WuXi AppTec and WuXi Biologics, citing strong performance and robust customer demand [2] - Goldman Sachs set a target price of HKD 63.3 for WuXi AppTec, reflecting confidence in the company's order momentum and customer demand [2]

该行提到，药明康德(603259.SH)A股为投资者带来理想的买入机会，上调公司2025至27年盈测3至4%， 并列为首选股;将药明生物(02269)2025至27年盈测调升6至13%;升药明合联(02268)盈测7至8%。综合而 言，三间公司2024至27年的盈利复合年增长率分别为24%、23%及37%。 智通财经APP获悉，摩根士丹利发布研报称，中国医疗保健股自9月中旬起被持续抛售，投资者正在获 利了结，并等待明年业绩发展的讯号。该行指出，当中药明系在基本面持续稳健的背景下，估值水平更 具吸引力。大摩最看好药明康德(02359)，因此该公司不仅上调业绩指引，更进行大规模产能扩张，且 在下一代GLP-1领域参与度高。 ...

Group 1 - The CRO concept stocks are experiencing a collective rebound, with the CSI Hong Kong Stock Connect Medical Theme Index rising by 2.73% as of November 24, 2025 [1] - Notable individual stock performances include Tigermed (03347) increasing over 9%, and other companies like Hansoh Pharmaceutical (03692), MicroPort Medical (00853), and WuXi AppTec (02359) also seeing gains [1][2] - The Hong Kong Medical ETF (159366) has risen over 2%, and over the past six months, it has accumulated a 29.35% increase [1][2] Group 2 - The innovative drug industry is benefiting from dual advantages of policy support and explosive demand, which are activating new drug research and development needs, positively impacting the CXO sector [3] - Among 29 listed companies in the A-share CXO sector, 20 reported year-on-year revenue growth in the first three quarters, indicating strong industry resilience [3] - WuXi AppTec's unique "integrated, end-to-end" CRDMO business model has driven steady growth, with total revenue of 32.86 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.6%, and net profit attributable to shareholders rising by 84.8% to 12.08 billion yuan [3] Group 3 - The high growth of the CXO sector is supported by the trend of pharmaceutical companies outsourcing R&D and production to specialized CXO firms, which helps reduce costs and improve efficiency [4] - CXO companies are enhancing their service capabilities through continuous technological development and scale expansion, leading to deeper integration with pharmaceutical companies [4] - As of October 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index accounted for 62.83% of the index, indicating a high concentration in the market [4]

Group 1 - CRO concept stocks have collectively rebounded, indicating a positive trend in the sector [1] - Tigermed (03347.HK) increased by 9.19%, reaching HKD 39.92 [1] - WuXi AppTec (02359.HK) rose by 4.43%, trading at HKD 106 [1] - Kanglong Chemical (03759.HK) saw a 4.15% increase, priced at HKD 21.58 [1] - WuXi Biologics (02269.HK) experienced a 3.27% rise, with a price of HKD 31.56 [1]